ty -jour t1 -copd加剧中的levofloxacin versus clarithromycin：专注于无加剧的间隔JF-欧洲呼吸杂志JO -EUR RESSIR J SP -947 LP -947 LP -953 DO -10.1183/109031936.04.004.0044.004.0044.0044.0044.0044.0044.0044.0044.00944.00966604 VL--24 IS -6 Au -Lode，H。Au -Eller，J。Au -Linnhoff，A.Au -ioanas，M。Au-au-评估COPD患者的无治疗间隔研究组Y1-2004/12/01 UR-http：//www.qdcxjkg.com/content/24/6/6/947.Abstract N2-慢性阻塞性肺疾病（COPD）细菌加剧的抗生素治疗（COPD）显示出一些直接的临床益处，并可能最小化进一步复发的频率。将患者（n = 511）纳入一项随机双盲中心研究，比较了7天左氧氟沙星与10天Clarithromycin的COPD患者的无效间隔（EFI），疗效和安全性，疗效和安全性。在1年期间监测患者。共有434名患者（每个方案人群）接受了≥5天的药物。左氧氟沙星的每规程人群中位数为300天，克拉霉素的中位数为350天。对于随访期间有新的病历加重的患者（n = 223），左氧氟沙星组的EFI中位数为100.5天，克拉霉素为95天。根据微生物病因和支气管阻塞的严重程度对研究人群进行分层时，群体之间的EFI之间没有显着差异。左氧氟沙星和克拉霉素显示出相似的临床成功率。 The bacteriological success rate was significantly higher in the levofloxacin group. Both antibiotics were well tolerated. In summary, levofloxacin was associated with a significantly higher bacteriological eradication rate but similar exacerbation-free interval in patients with chronic obstructive pulmonary disease exacerbation compared to clarithromycin. This study was supported by a grant from Aventis Pharma, Bad Soden, Germany. ER -